Loading...
Correction: combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Zanjirband, M. Curtin, N. Edmondson, Richard J Lunec, J.
Zanjirband, M.
Curtin, N.
Edmondson, Richard J
Lunec, J.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Other
Citation
Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget. 2024 Feb 22;15:142. PubMed PMID: 38386812. Pubmed Central PMCID: PMC10883681. Epub 2024/02/22. eng.